The maternal care startup is backed by major health systems including MemorialCare Health System, whose innovation arm led the most recent funding round. Babyscripts offers a mobile app providing education and resources for the pregnancy and postpartum journey.
Together, the Tennessee-based health system and health technology company will develop solutions to help clinicians detect diseases faster. The new agreement builds on an existing partnership that focuses on earlier diagnoses for lung cancer.
The solution will connect providers with social services organizations, enabling the secure exchange of messages, referrals and personal health information. The FHIR-based technology can help providers factor in social determinants of health when caring for their patients.
Through the new partnership, Redox — which connects EHRs to healthcare products and services — will make Withings’ remote patient monitoring solution compatible with nearly all EHRs used by physicians and hospitals.
A video from the conference spotlights startup pitches and Q&A with judges in the Life Science track of the Pitch Perfect contest.
The final day of the conference, Friday, December 11, includes a panel on precision medicine investment trends, a look at clinical trial design innovation and the life sciences track of our Pitch Perfect startup contest. Register now!
Among the areas of interest for companies presenting at Pitch Perfect at INVEST Precision Medicine are clinical stroke detection, making medical research more inclusive, using technology to accelerate the pace of clinical trials, developing more patient friendly drug delivery systems for reconstitutable drugs, and more.
Shots: Qiagen launches QuantiFERON SARS-CoV-2 RUO solution that detects T-cell responses of the human immune system to the pathogen for COVID-19 Studies suggested that T-cell response to SARS-CoV-2 declines more slowly than Ab response presenting benefits to a researcher who wants to push beyond the existing detection of active infections to screen for potential courses …
Shots: The P-III study involves assessing Xywav vs PBO in patients aged ≥ 7yrs. with cataplexy or EDS with narcolepsy Results: study met its 1EPs & 2EPs i.e. differences in median change in a weekly number of cataplexy attacks and ESS scores. Results were published at World Sleep 2019 Xywav is an oxybate product with …